^Jung, Michael E.; Yoo, Dongwon (January 2008). "Synthesis of the C1–C12 fragment of the tedanolides. Selective hydroboration–protonation of allylic alcohol approach". Tetrahedron Letters. 49 (5): 816–819. doi:10.1016/j.tetlet.2007.11.181.
^Jung, Michael E.; Lee, Christopher P. (February 2001). "Synthesis of a Fully Functionalized Protected C1−C11 Fragment for the Synthesis of the Tedanolides". Organic Letters. 3 (3): 333–336. doi:10.1021/ol000329p. PMID11428007.
^Jung, Michael E; Lee, Christopher P (December 2000). "Use of the non-aldol aldol process in the synthesis of the C1–C11 fragment of the tedanolides: use of lactol ethers in place of tetrahydrofurans". Tetrahedron Letters. 41 (50): 9719–9723. doi:10.1016/s0040-4039(00)01726-3.
^Jung, Michael E.; Nichols, Christopher J. (October 1996). "Highly stereoselective synthesis of trans,trans-4-aryl-2,3-oxetanedimethanols: Preparation of oxetanocin a analogues". Tetrahedron Letters. 37 (43): 7667–7670. doi:10.1016/0040-4039(96)01720-0.
^Jung, Michael E.; Parker, Michael H. (1 October 1997). "Synthesis of Several Naturally Occurring Polyhalogenated Monoterpenes of the Halomon Class1". The Journal of Organic Chemistry. 62 (21): 7094–7095. doi:10.1021/jo971371+. ISSN0022-3263. PMID11671809.
^Jung, Michael E; Johnson, Ted W (February 2001). "First total synthesis of xestobergsterol A and active structural analogues of the xestobergsterols". Tetrahedron. 57 (8): 1449–1481. doi:10.1016/s0040-4020(00)01086-3.
^"New Prostate Cancer Agent Class: Rational design leads to novel drug candidate, now in clinical trials", Chemical and Engineering News, September 22, 2008, Volume 86, Number 38 pp. 84-87